Director of CDC, Rochelle Walensky Warns of ADE, Antibody Dependent Enhancement From Israel Data
According to Robert Malone, MD inventor of the mRNA vaccine technology, a dreaded adverse side effect of COVID-19 vaccines is ADE, Antibody Dependent Enhancement which has been described in animal studies.(29)(31) This is the interaction of the immune system with the virus resulting in death of most of the vaccinated animals upon re-exposure to the virus. Obviously, this is not a good thing. (16-17)
ADE Explained: Two Types of Antibodies
In this scenario, there are two types of antibodies in the experimental animals. The first type is the neutralizing antibodies and the second type is the enhancing antibodies. The neutralizing antibodies are preferred since they “neutralize” or completely eliminate the virus from the body. The enhancing antibodies are the problem since they “enhance” entry of the virus into cells, enhancing viral replication and severity of the disease. Enhancing antibodies do exactly the opposite of the intended effect of the vaccine. Instead of protecting the animal, the vaccine makes the viral disease worse and kills the animal.(1-15)
Previous Failed Human Vaccine Trials
Previous human vaccines against RSV and Dengue virus resulted in failed vaccine trials because of ADE, Antibody Dependent Enhancement. In the Philippines, failure of the Dengue vaccine program led to criminal charges for researchers. 830,000 children were given the “Dengvaxia”, Dengue virus vaccine, before the program was suspended in 2017. (11-13) Dr Wen Shi Lee writes in Nature Microbiology (2020):
Previous respiratory syncytial virus and dengue virus vaccine studies revealed human clinical safety risks related to ADE, resulting in failed vaccine trials. (3) Endquote Dr. Lee
So far, with the mRNA COVID 19 vaccine, we have not seen this ADE to any appreciable degree in the US. However, early data from Israel suggests ADE is starting to appear in the vaccinated population, those who received their vaccination the earliest.
What is the significance of receiving your vaccine the earliest ? Pfizer is now recommending a third booster shot after 6 months, admitting the vaccine induced antibody protection wanes after 6 months or so. (14-15) In Australia, Dr Kerry Chant is bluntly stating everyone will need to get a booster vaccine every 6 months “forever”. This is an obvious admission of vaccine failure. Here is Zero Hedge quoting Dr Kerry Chant, the Australian Health Minister:
“Australian health chief Dr. Kerry Chant says that COVID will be with us “forever” and people will have to “get used to” taking endless booster vaccines.” end quote
Antibodies Wane After 6 Months
As antibodies wane, the patient is now at risk for viral infection after vaccination as we have been seeing with “break through” cases. This is the predicted scenario for ADE, and prompted Pfizer to recommend a third booster shot to avoid catastrophic ADE, as was seen with the Dengue virus in the Philippines.(1-15)
Dr. Rochelle Walensky
Watch this video of CDC Director Rochelle Walensky who warns about ADE, or worsening disease in vaccinated individuals after re-exposure to the virus :
“Additionally, reports from our international colleagues, including Israel, suggest increased risk of severe disease amongst those vaccinated early.” Endquote Dr. Rochelle Walensky
Conclusion: Rachelle Walensky of the CDC is now warning us about ADE , Antibody Dependent Enhancement. This is an adverse effect in which the vaccine makes the disease worse. Some authors have suggested abandoning the current mRNA vaccines in favor of new vaccines using T cell immunity rather than antibody immunity.(5) Dr. Darrell O Ricke writes in Frontiers in immunology (2021):
These models place increased emphasis on the importance of developing safe SARS-CoV-2 T cell vaccines that are not dependent upon antibodies. (5) endquote Dr. Darrell O Ricke
Vaccination is Eighteenth Century Obsolete Technology
If ADE occurs to any extent in the vaccinated population, this could trigger loss of confidence in vaccination. We would all wake from the hypnotic sleep and realize “vaccination” is an obsolete medical intervention from the eighteenth century, a time before modern medicine with all its knowledge of virology, molecular biology and repurposed drug treatment of viral disease.
The Invention of Vaccination
In the 1700’s, people noticed that milk maids seemed to have immunity from smallpox, thought to be due to exposure to a virus in cows called “cow pox”. In 1796, Edward Jenner was the first to inject cow pox “pus” into people, naming it “vaccination” from “vacca”, the Latin word for cow. This was done at a time before the invention of modern medicine, with no understanding of virology or molecular biology, and no modern drugs or therapeutics.
An Obsolete Intervention from the Eighteenth Century
Like the use of bloodletting and leeches, I would propose that vaccination of the eighteenth century has been made obsolete by modern therapeutics. This is especially true for the failed mRNA vaccine program for COVID. (26) With the advent of modern medicine, we now have highly effective early multi-drug antiviral treatment for COVID 19 with Ivermectin, Hydroxychloroquine, Zinc, Budesonide, Aspirin, Azithromycin, Doxycycline. These are repurposed drugs used off-label as discussed in previous newsletters. (24-26)
Early Treatment Superior the Vaccination
Early treatment facilitates rapid recovery, resulting in natural immunity more durable and more robust than vaccination.(21)(27-30) One must ask the question, why submit to an experimental vaccine with new data showing it to be dangerous and ineffective, requiring a “booster” every 6-12 months, when we have a better approach with highly effective early treatment with multi-drug therapy that provides superior natural immunity?
Robert Malone MD Discussing ADE
Update 8/24/21: FDA Approves Pfizer-BioNTech COVID-19 Vaccine
One might wonder how a vaccine could be FDA approved when there were more deaths in the vaccine arm than in the placebo arm. (15 vs. 14) See this BMJ article by Peter Doshi:
Does the FDA think these data justify the first full approval of a covid-19 vaccine? August 23, 2021 Peter Doshi Associate Editor of the BMJ British Medical Journal writes the FDA should make the data publicly available, and address open questions of efficacy and safety before granting full approval:
“The FDA should demand adequate, controlled studies with long term follow up, and make data publicly available, before granting full approval to covid-19 vaccines…my view, along with a group of around 30 clinicians, scientists, and patient advocates, was that there were simply too many open questions about all covid-19 vaccines to support approving any this year. The preprint has, unfortunately, addressed very few of those open questions, and has raised some new ones…I reiterate our call: “slow down and get the science right—there is no legitimate reason to hurry to grant a license to a coronavirus vaccine….There were 29 total deaths during blinded follow-up (15 in the vaccine arm; 14 in placebo)”. END Quote Peter Doshi BMJ (emphasis mine)
Problem Number 1) Submitted Data shows no lives were saved by the vaccine. There were more deaths in the vaccine arm than the placebo arm (15 vs. 14)
Problem Number 2) The data submitted to the FDA is outdated data dealing with the earlier Alpha and Beta variants. The prevailing variant is now the Delta variant for which there was no data submitted. Israeli data suggests Vaccine efficacy against the Delta variant is in the range of 40%, much lower than earlier variants.
Problem Number 3) The FDA decided to skip input from their advisory committee, and skip any public comment. This is highly unusual and indicates lack of transparency.
Problem Number 4) Dr. Malone says there were 2 approval letters representing a “shell game”. Full approval was granted only for the BioNTech labeled product (for ages 16 and up), While EUA (Emergency Use Authorization) was extended for the Pfizer label product (and the age 12-16). Aren’t they the same vaccine? Why the shell game ? The answer can be found HERE .
Update 8/27/21: Israeli study shows Natural Immunity is Superior to Two dose vaccination for the Delta Variant. (21)
Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections by Sivan Gazit, MD MA1,2*; Roei Shlezinger, BA1; Galit Perez, MN MA2; Roni Lotan, PhD2; Asaf Peretz, MD1,3; Amir Ben-Tov, MD1,4; Dani Cohen, PhD4; Khitam Muhsen, PhD4; Gabriel Chodick, PhD MHA2,4; Tal Patalon, MD1,
This study demonstrated that natural immunity confers longer lasting and stronger protection against infection, symptomatic disease and hospitalization caused by the Delta variant of SARS-CoV-2, compared to the BNT162b2 two-dose vaccine-induced immunity. end quote
Update 9/15/21 Marty Makary MD Natural Immunity is Powerful Washington Post….
Ĉ0\/lÐ Recovery Ĉonfers N@tur@l lʍʍunity Superior to \/@ĉĉine lʍʍunity….700,000-person study from Israel 9/1/21: people with prior Ĉ0\/lÐ infection are 27 times less likely to get a second symptomatic Ĉ0\/lÐ infection than those who were \/@ĉĉin@ted !!!! and even a mild covid infection resulted in long-lasting immunity. (Turner, 2021, Nature)
Turner, Jackson S., et al. “SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans.” Nature (2021): 1-5. “Our results indicate that mild infection with SARS-CoV-2 induces robust antigen-specific, long-lived humoral immune memory in humans.” (5/24/21 Washington University)
Articles with Related Interest
Jeffrey Dach MD
7450 Griffin Road Suite 180/190
Davie, Florida 33314
Links and References
Header image courstesy of Rochelle Walensky and Wikimedia Commons File:CDC-Director-Rochelle-Walensky-Headshot.jpg
1) Nouara Yahi Henri Chahinian Jacques Fantini August 09, 2021 Letter to the Editor, Journal of Infection , Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination ?
• Infection-enhancing antibodies have been detected in symptomatic Covid-19
• Antibody dependent enhancement (ADE) is a potential concern for vaccines
• Enhancing antibodies recognize both the Wuhan strain and Delta variants
• ADE of Delta variants is a potential risk for current vaccines
• Vaccine formulations lacking ADE epitope are suggested
Antibody dependent enhancement (ADE) of infection is a safety concern for vaccine strategies. In a recent publication, Li et al. (Cell 184 :1-17, 2021) have reported that infection-enhancing antibodies directed against the N-terminal domain (NTD) of the SARS-CoV-2 spike protein facilitate virus infection in vitro, but not in vivo. However, this study was performed with the original Wuhan/D614G strain. Since the Covid-19 pandemic is now dominated with Delta variants, we analyzed the interaction of facilitating antibodies with the NTD of these variants. Using molecular modelling approaches, we show that enhancing antibodies have a higher affinity for Delta variants than for Wuhan/D614G NTDs. We show that enhancing antibodies reinforce the binding of the spike trimer to the host cell membrane by clamping the NTD to lipid raft microdomains. This stabilizing mechanism may facilitate the conformational change that induces the demasking of the receptor binding domain. As the NTD is also targeted by neutralizing antibodies, our data suggest that the balance between neutralizing and facilitating antibodies in vaccinated individuals is in favor of neutralization for the original Wuhan/D614G strain. However, in the case of the Delta variant, neutralizing antibodies have a decreased affinity for the spike protein, whereas facilitating antibodies display a strikingly increased affinity. Thus, ADE may be a concern for people receiving vaccines based on the original Wuhan strain spike sequence (either mRNA or viral vectors). Under these circumstances, second generation vaccines with spike protein formulations lacking structurally-conserved ADE-related epitopes should be considered.
2) Risk of COVID‐19 vaccines worsening clinical disease
1. THE RISK OF ADE IN COVID‐19 VACCINES IS NON‐THEORETICAL AND COMPELLING
Vaccinees at higher risk for more severe COVID‐19 disease when they encounter circulating viruses.
3) Lee, Wen Shi, et al. “Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies.” Nature microbiology 5.10 (2020): 1185-1191.
Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data from the study of SARS-CoV and other respiratory viruses suggest that anti-SARS-CoV-2 antibodies could exacerbate COVID-19 through antibody-dependent enhancement (ADE). Previous respiratory syncytial virus and dengue virus vaccine studies revealed human clinical safety risks related to ADE, resulting in failed vaccine trials. Here, we describe key ADE mechanisms and discuss mitigation strategies for SARS-CoV-2 vaccines and therapies in development. We also outline recently published data to evaluate the risks and opportunities for antibody-based protection against SARS-CoV-2.
4) Wen, Jieqi, et al. “Antibody-dependent enhancement of coronavirus.” International Journal of Infectious Diseases (2020).
Antibody-dependent enhancement (ADE) exists in several kinds of virus. It has a negative influence on antibody therapy for viral infection. This effect was first identified in dengue virus and has since also been described for coronavirus. To date, the rapid spread of the newly emerged coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus disease 2019 (COVID-19), has affected over 3.8 million people across the globe. The novel coronavirus poses a great challenge and has caused a wave of panic. In this review, antibody-dependent enhancements in dengue virus and two kinds of coronavirus are summarized. Possible solutions for the effects are reported. We also speculate that ADE may exist in SARS-CoV-2.
5) Ricke, Darrell O. “Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies.” Frontiers in immunology 12 (2021): 443.
COVID-19 (SARS-CoV-2) disease severity and stages varies from asymptomatic, mild flu-like symptoms, moderate, severe, critical, and chronic disease. COVID-19 disease progression include lymphopenia, elevated proinflammatory cytokines and chemokines, accumulation of macrophages and neutrophils in lungs, immune dysregulation, cytokine storms, acute respiratory distress syndrome (ARDS), etc. Development of vaccines to severe acute respiratory syndrome (SARS), Middle East Respiratory Syndrome coronavirus (MERS-CoV), and other coronavirus has been difficult to create due to vaccine induced enhanced disease responses in animal models. Multiple betacoronaviruses including SARS-CoV-2 and SARS-CoV-1 expand cellular tropism by infecting some phagocytic cells (immature macrophages and dendritic cells) via antibody bound Fc receptor uptake of virus. Antibody-dependent enhancement (ADE) may be involved in the clinical observation of increased severity of symptoms associated with early high levels of SARS-CoV-2 antibodies in patients. Infants with multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 may also have ADE caused by maternally acquired SARS-CoV-2 antibodies bound to mast cells. ADE risks associated with SARS-CoV-2 has implications for COVID-19 and MIS-C treatments, B-cell vaccines, SARS-CoV-2 antibody therapy, and convalescent plasma therapy for patients. SARS-CoV-2 antibodies bound to mast cells may be involved in MIS-C and multisystem inflammatory syndrome in adults (MIS-A) following initial COVID-19 infection. SARS-CoV-2 antibodies bound to Fc receptors on macrophages and mast cells may represent two different mechanisms for ADE in patients. These two different ADE risks have possible implications for SARS-CoV-2 B-cell vaccines for subsets of populations based on age, cross-reactive antibodies, variabilities in antibody levels over time, and pregnancy. These models place increased emphasis on the importance of developing safe SARS-CoV-2 T cell vaccines that are not dependent upon antibodies.
6) Wang, Jiong, and Martin S. Zand. “The potential for antibody-dependent enhancement of SARS-CoV-2 infection: Translational implications for vaccine development.” Journal of Clinical and Translational Science 5.1 (2021).
There is an urgent need for vaccines to the 2019 coronavirus (COVID19; SARS-CoV-2). Vaccine development may not be straightforward, due to antibody-dependent enhancement (ADE). Antibodies against viral surface proteins can, in some cases, increase infection severity by ADE. This phenomenon occurs in SARS-CoV-1, MERS, HIV, Zika, and dengue virus infection and vaccination. Lack of high-affinity anti-SARS-CoV-2 IgG in children may explain the decreased severity of infection in these groups. Here, we discuss the evidence for ADE in the context of SARS-CoV-2 infection and how to address this potential translational barrier to vaccine development, convalescent plasma, and targeted monoclonal antibody therapies.
7) Farshadpour, Fatemeh, and Reza Taherkhani. “Antibody-Dependent Enhancement and the Critical Pattern of COVID-19: Possibilities and Considerations.” Medical Principles and Practice (2021).
The pathogenicity of several viral infections is mediated by effector mechanisms of the immune system.
• Antibodies produced during the previous exposure to seasonal coronaviruses or possibly severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are proposed to trigger antibody-dependent enhancement.
• Antibody-dependent enhancement might lead to more severe and lethal illness upon infection with SARS-CoV-2, results in cytokine storm and tissue damage, and can modulate immune responses to-ward an inflammatory profile.
8) Bastug, Aliye, and Hurrem Bodur. “SARS-CoV-2 Infection and Antibody-Dependent Enhancement.” Understanding COVID-19: The Role of Computational Intelligence. Springer, Cham, 2022. 101-113.
Although there exist insufficient data, the titers of antibodies have been reported to be decreasing rapidly, suggesting a risk of reinfection. If reinfection occurs, another concern is whether it will be more severe due to the preexisting low level antibodies. To combat the continuing pandemic, antibody-based treatments, such as monoclonal antibodies (mAbs), convalescent plasma (CP) therapies, and vaccine studies, have been investigated. Although it may not be as troublesome as in the Dengue fever, clinicians should be alert about the possible risk of ADE. Non-neutralizing antibodies or sub-protective levels of NAbs may trigger immunopathogenic events via immune complex-mediated or Fc receptor-dependent endocytosis, resulting in enhanced viral infection. In this chapter, literature findings revealing the factors with an impact on eliciting NAbs, possible mechanisms and risks of ADE, and safety concerns for SARS-CoV-2 treatment interventions are outlined.
9) Khan, Kashif Rehman. “Antibody Dependent Disease Enhancement and the Covid-19 Vaccine: A Word of Caution.”
Antibody-Dependent Enhancement (ADE), refers to a counter-intuitive and potentially dangerous situation when the presence of antibodies, which are supposed to vanquish disease, worsens rather than quells an infection.
➢ In ADE, instead of neutralizing the virus, host antibodies, designated as non-neutralizing antibodies, facilitate its infectivity.
➢ Both Intrinsic and Extrinsic ADE work in tandem to enhance viral disease by increasing the number of cells getting infected and decreasing the innate response of body against that infection.
➢ It is important for scientists to consider ADE before progressing to clinical trials
SARS CoV-2 vaccines are being advertised as a tool to beat COVID-19, yet with the emergence of different variants that are suggested to be vaccine-resistant, and the emergence of SARS CoV-2 vaccine induced serious adverse effects a personalized risk benefit ratio should be carefully assessed. mRNA based and adenovirus vectored vaccines, types of nucleic acid-based vaccination, were first ever or first commercially ever approved for the public, respectively. However, these new types possess a potential risk to induce auto-immune diseases e.g., thrombocytopenia and some of these complications might also reason for some of the post vaccination sudden death reports e.g., autoimmune myocarditis and immune induced thrombosis and thromboembolism. Moreover, all SARS CoV-2 types of vaccines, depending on the spike protein immunogenicity, especially the conventional inactivated ones might increase the likelihood of COVID-19 severity upon re-infection through antibody dependent enhancement which might also reason for some of the serious adverse effects encountered with administration of convalescent plasma to COVID-19 patients. Moreover, these vaccines might have shared in development of the potentially more lethal SARS CoV-2 B.1.617 variants and might lead to evolution of more virulent ones. Finally, A moral, legal, and sacred constitutional public right to know and decide basing on a personalized risk benefit ratio must be secured. Finally, it is a real misfortune that a draft of this manuscript is being denied an opportunity to be properly peer reviewed by numerous reputable medical journals for more than six months and even before a single mortality was reported and we totally condemn, from a medical point of view, any national or international policy that necessitates these experimental vaccines and we also condemn the trials in children as well as the European Court of Human Rights shameful ruling that compulsory vaccination would not contravene human rights law and we suggest that the rapid race to develop and approve SARS CoV-2 vaccines might eventually end with a man-made Hades.
11) Dengue vaccine fiasco leads to criminal charges for researcher in the Philippines By Fatima Arkin Apr. 24, 2019 , SCience Magazine
A prominent pediatrician and medical researcher in the Philippines has been indicted over the failed—and many say premature—introduction of Dengvaxia, a vaccine against dengue that was yanked from the Philippine market in 2017 because of safety issues. If convicted of accusations leveled at her by the national Department of Justice (DOJ), Rose Capeding, 63, former head of the dengue department of the Research Institute for Tropical Medicine (RITM) here, could face up to 48 years in prison.
In September 2018, DOH Undersecretary Enrique Domingo told reporters that 130 vaccinated children had died; 19 of those had dengue, meaning ADE possibly played a role. The case triggered “mass hysteria,” says Edsel Salvaña, an infectious disease physician at the University of the Philippines here. “Parents thought their kids were all going to die.”
12) Wilder-Smith, Annelies, Stefan Flasche, and Peter G. Smith. “Vaccine-attributable severe dengue in the Philippines.” The Lancet 394.10215 (2019): 2151-2152.
In 2016, WHO1 recommended that the dengue vaccine CYD-TDV (Dengvaxia; Pasteur, Lyon, France), the first dengue vaccine, licensed for use in adults and children aged 9 years or older, be considered for use in highly endemic regions where at least 70% of 9-year-old children had previously been infected with dengue. The Philippines was the first country to introduce Dengvaxia on a large scale in selected highly endemic regions, targeting about 1 million children aged 9–10 years. In November, 2017, an excess risk of hospitalisation for dengue and severe dengue in vaccinees who had not had a previous dengue infection at the time of vaccination was reported,2 on the basis of retrospective analyses3 of data from the Dengvaxia phase 3 trials, using a novel non-structural protein 1 (NS1) based antibody assay. Following a reanalysis of these data,3 the Philippine Dengvaxia programme was suspended. However, by the time the programme had been suspended, more than 830 000 children had received at least one of the three recommended Dengvaxia doses. The news about the safety concerns in dengue-naive vaccinees led to major public outcry, with loss in vaccine confidence that extended to routine childhood vaccines.4
13) Larson, Heidi J., Kenneth Hartigan-Go, and Alexandre de Figueiredo. “Vaccine confidence plummets in the Philippines following dengue vaccine scare: why it matters to pandemic.” Human Vaccines & Immunotherapeutics.
In November 2017, it was announced that the new dengue vaccine (“Dengvaxia”) had risks for those not previously exposed to dengue. While some countries proceeded with adjusting guidance accordingly, the Philippines reacted with outrage and political turmoil with naming and shaming of government officials involved in purchasing the vaccine, as well as scientists involved in the vaccine trials and assessment. The result was broken public trust around the dengue vaccine as well heightened anxiety around vaccines in general. The Vaccine Confidence ProjectTM measured the impact of this crisis, comparing confidence levels in 2015, before the incident, with levels in 2018. The findings reflect a dramatic drop in vaccine confidence from 93% “strongly agreeing” that vaccines are important in 2015 to 32% in 2018. There was a drop in confidence in those strongly agreeing that vaccines are safe from 82% in 2015 to only 21% in 2018; similarly confidence in the effectiveness of vaccines dropped from 82% in 2015 to only 22%.
14) CDC warns of a “significant decline” in vaccine effectiveness for some, prompting booster dose decision By Alexander Tin Updated on: August 18, 2021 CBS News
New data being released Wednesday by the Centers for Disease Control and Prevention warns of a “significant decline” in vaccine effectiveness against infection from COVID-19 in nursing home residents, as the highly contagious Delta variant of the virus causes a spike in hospitalizations among mostly unvaccinated Americans.
The release came as the Biden administration says it is preparing to offer booster shots for all Americans who got the Pfizer or Moderna vaccines, eight months after their second dose, beginning the week of September 20.
“Given this body of evidence, we are concerned that the current strong protection against severe infection, hospitalization and death could decrease in the months ahead, especially among those who are at higher risk or who were vaccinated earlier,” CDC Director Dr. Rochelle Walensky said at a briefing Wednesday.
16) mRNA vaccine inventor: COVID-19 vaccines may make virus more dangerous Dr. Robert Malone warns that the development of antibody dependent enhancement among those vaccinated with COVID vaccines ‘is the vaccinologist’s worst nightmare.’ The scientist has recently been calling for a halt to vaccinations.
18) Dr Peter McCullough Podcast America Out Loud Vaccinated Become Persons of Interest August 22
19) “The failed mass Covid-19 vaccination programme will go down as one of the most deadly in history” By Daily Expose on August 26, 2021
“The forced mass vaccination of humanity will be regarded as one of the most deadly and costly medical mistakes in history, renowned pioneer in the early treatment of the alleged Covid-19 disease, Texas cardiologist and internist Dr. Peter McCullough, has said.”
20) Luc Montagnier on ADE Antibody Dependent Enhancement UncoverDC Michelle Edwards Aug 2021
21) Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity : reinfections versus breakthrough infections. Sivan Gazit, MD MA1,2*; Roei Shlezinger, BA1; Galit Perez, MN MA2; Roni Lotan,
PhD2; Asaf Peretz, MD1,3; Amir Ben-Tov, MD1,4; Dani Cohen, PhD4; Khitam Muhsen, PhD4; Gabriel Chodick, PhD MHA2,4; Tal Patalon, MD1,
This study demonstrated that natural immunity confers longer lasting and stronger protection against infection, symptomatic disease and hospitalization caused by the Delta variant of SARS-CoV-2, compared to the BNT162b2 two-dose vaccine-induced immunity.
22) COVID-19 Mandates Will Not Work for the Delta Variant
Paul E. Alexander – August 28, 2021
23) Dr James Neuenschwander: Vaccine Is Killing People And Does Not Stop The Spread
24) McCullough, Peter A., et al. “Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19).” Reviews in cardiovascular medicine 21.4 (2020): 517.
The SARS-CoV-2 virus spreading across the world has led to surges of COVID-19 illness, hospitalizations, and death. The complex and multifaceted pathophysiology of life-threatening COVID-19 illness including viral mediated organ damage, cytokine storm, and thrombosis warrants early interventions to address all components of the devastating illness. In countries where therapeutic nihilism is prevalent, patients endure escalating symptoms and without early treatment can succumb to delayed in-hospital care and death. Prompt early initiation of sequenced multidrug therapy (SMDT) is a widely and currently available solution to stem the tide of hospitalizations and death. A multipronged therapeutic approach includes 1) adjuvant nutraceuticals, 2) combination intracellular anti-infective therapy, 3) inhaled/oral corticosteroids, 4) antiplatelet agents/anticoagulants, 5) supportive care including supplemental oxygen, monitoring, and telemedicine. Randomized trials of individual, novel oral therapies have not delivered tools for physicians to combat the pandemic in practice. No single therapeutic option thus far has been entirely effective and therefore a combination is required at this time. An urgent immediate pivot from single drug to SMDT regimens should be employed as a critical strategy to deal with the large numbers of acute COVID-19 patients with the aim of reducing the intensity and duration of symptoms and avoiding hospitalization and death.
25) Bruno, Roxana, et al. “SARS-CoV-2 mass vaccination: Urgent questions on vaccine safety that demand answers from international health agencies, regulatory authorities, governments and vaccine developers.” (2021). Peter A Mccullough . SARS-CoV2 mass vaccination Urgent questions on vaccine safety
26) Dr Peter Mccoulough, Covid Vaccines Are Obsolete. July 26, 2021 (LifeSiteNews) — The John-Henry Westen Show, Dr. Peter A. McCullough, the most qualified physician on COVID-19 in the United States. Natural Immunity is Robust and Durable. Covid Variants DO NOT Penetrate natural immunity. Covid easily treatable at home with early treatment. Current vaccines are obsolete , they do not cover new variants. Current Covid Vaccines account for record mortality and mortality and are unfit for human use.
27) Shrestha, Nabin K., et al. “Necessity of COVID-19 vaccination in previously infected individuals.” medRxiv (2021). Cleveland Clinic.
Results Among the 52238 included employees, 1220 (47%) of 2579 previously infected subjects received the vaccine, compared with 29461 (59%) of 49659 not previously infected. The cumulative incidence of SARS-CoV-2 infection did not differ among previously infected unvaccinated subjects, previously infected subjects who were vaccinated, and previously uninfected subjects who were vaccinated, and was much lower than that of previously uninfected subjects who remained unvaccinated. Not one of the 1359 previously infected subjects who remained unvaccinated had a SARS-CoV-2 infection over the duration of the study.
Conclusion: Individuals who have had SARS-CoV-2 infection are unlikely to benefit from COVID-19 vaccination, and vaccines can be safely prioritized to those who have not been infected before.
28) CNBC: You can’t sue Pfizer or Moderna if you have severe Covid vaccine side effects. The government likely won’t compensate you for damages either Dec 17 2020 MacKenzie Sigalos CNBC
Singapore study shows that SARS-CoV-2-specific T cells are present in all recovered COVID-19 patients. These T cells were also found in all subjects who recovered from SARS 17 years ago, and in over 50% of both SARS-CoV-1 and SARS-CoV-2 uninfected individuals tested, suggesting that a level of pre-existing SARS-CoV-2 immunity is present in the general population. Infection and exposure to coronaviruses induces long-lasting memory T cells, which could help in the management of the current pandemic.
30) Durability of SARS-CoV-2-specific T cell responses at 12-months post-infection Zhongyan Lu and the EPICC COVID-19 Cohort Study Group (2021)
ADE Animal Studies
29) Tseng, Chien-Te, et al. “Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.” PloS one 7.4 (2012): e35421.
These SARS-CoV vaccines all induced antibody and protection against infection with SARS-CoV. However, challenge of mice given any of the vaccines led to occurrence of Th2-type immunopathology suggesting hypersensitivity to SARS-CoV components was induced. Caution in proceeding to application of a SARS-CoV vaccine in humans is indicated.
Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, United States of America,
2 Center for Biodefense and Emerging Disease, The University of Texas Medical Branch, Galveston, Texas, United States of America,
3 Department of Medicine, Baylor College of Medicine, Houston, Texas, United States of America,
4 Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, United States of America,German Primate Center, Germany
30) List of Failed Vaccines Withdrawn from the Market: Discontinued_Vaccines-1 add: Dengue (Dengvaxia), RSV vaccine
31) Vennema, H., et al. “Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization.” Journal of virology 64.3 (1990): 1407-1409.
The gene encoding the fusogenic spike protein of the coronavirus causing feline infectious peritonitis was recombined into the genome of vaccinia virus. The recombinant induced spike-protein-specific, in vitro neutralizing antibodies in mice. When kittens were immunized with the recombinant, low titers of neutralizing antibodies were obtained. After challenge with feline infectious peritonitis virus, these animals succumbed earlier than did the control group immunized with wild-type vaccinia virus (early death syndrome).
Life Site News The John-Henry Westen Show, Dr. Peter A. McCullough : COVID shots are ‘obsolete,’ dangerous, must be shut down Dr. Peter A. McCullough presents a real expert’s take on these crucial issues, as one of the top COVID doctors in the world.
Nurse raises hell…Posted by Kane on August 20, 2021 Citizen Free Press
7 Vaccinated Florida Patients Die of COVID; Nurse Calls Situation ‘Disturbing’ By Andrew Stanton On 8/17/21 at 10:47 AM EDT
Florida nurse said seven fully vaccinated patients died from COVID-19 in the past two weeks in a situation she as “heartbreaking.”
Patricia Seemann, who runs All About You Home Visiting Clinicians in Saint Cloud, told Newsweek in an interview Tuesday afternoon that before the deaths, she had successfully treated hundreds of patients with COVID-19. She said she works with housebound patients who are over 60 years old and are at high-risk of COVID-19 related deaths. “We didn’t lose a single patient,” she said.
Massive Nurse Shortage Hits Houston—Weeks After 150 Unvaccinated Nurses and Hospital Workers Fired
Houston hospitals have “reached a breaking point” amid a COVID-19 outbreak, which struck weeks after 150 hospital workers were fired by Houston Methodist hospital, one of several hospitals struggling.
Wednesday, August 18, 2021
BRAVE NURSE EXPOSES CDC & FAUCI LIES — REGISTERED NURSE NICOLE
A courageous registered nurse named Nicole has come forward to blow the whistle on the CDC, Dr. Fauci & the mainstream mockingbird media’s covid “vaccine” lies.
Dr. Byram Bridle / Viral Immunologist at the University of Guelph
First published at 20:44 UTC on August 19th, 2021. Career Destroyed for speaking about COVID Vaccine.
WATCH: Perspectives on the Pandemic #17 “2020 and 2021 have comprised a global propaganda spectacle of unprecedented scale and sophistication.” Off Guardian. Mark Crispin Miller is Professor of Media, Culture and Communication at New York University
WATCH: Perspectives on the Pandemic #18 “One of the things that Covid rollout has done, is create a whole new category of forbidden speech…if you’re not completely credulous then you’re somehow “putting people at risk”. Off Guardian. Mark Crispin Miller is Professor of Media, Culture and Communication at New York University
The Delingpod: POD-CAST The James Delingpole Podcast » Mark Crispin Miller 8/20/21 1 hr 47 minutes
Life in a Year from Now on You Tube
Jeffrey Dach MD
7450 Griffin Road, Suite 190
Davie, Fl 33314
Heart Book by Jeffrey Dach
Click Here for: Dr Dach’s Online Store for Pure Encapsulations Supplements
Click Here for: Dr Dach’s Online Store for Nature’s Sunshine Supplements
Web Site and Discussion Board Links:
The reader is advised to discuss the comments on these pages with his/her personal physicians and to only act upon the advice of his/her personal physician. Also note that concerning an answer which appears as an electronically posted question, I am NOT creating a physician — patient relationship. Although identities will remain confidential as much as possible, as I can not control the media, I can not take responsibility for any breaches of confidentiality that may occur.
Link to this Article
Copyright (c) 2021 Jeffrey Dach MD All Rights Reserved. This article may be reproduced on the internet without permission, provided there is a link to this page and proper credit is given. See Repost Guidelines.